Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
Belanoff et al. • 2010 • Diabetes Obes Metab. 2010;12(6):545-7.
Belanoff et al. • 2010 • Diabetes Obes Metab. 2010;12(6):545-7.
Elhassan et al • 2019 • Ann Intern Med.
Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.
Hunt et al. • 2017 • J Med Chem. 2017;60(8):3405-3421.
Clark et al. • 2008 • Bioorg Med Chem Lett. 2008;18(4):1312-7.
Hunt et al. • 2017 • Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.
Bali et al. • 2016 • J Clin Endocrinol Metab. 2016;101(11):4305-4312.
Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.
Kroon et al. • 2017 • Endocrinology. 2017 Sep 18. doi:10.1210/en.2017-00512.
Mammi et al. • 2016 • Int J Obes (Lond). 2016;40(6):964-72.
© 2024 Corcept Therapeutics, Incorporated